![Retina associates of kentucky](https://loka.nahovitsyn.com/49.jpg)
![retina associates of kentucky retina associates of kentucky](https://www.retinaky.com/wp-content/themes/glacial/images/callout2-img.png)
Retina associates of kentucky update#
Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone.
![retina associates of kentucky retina associates of kentucky](https://www.asrs.org/content/images/cms/robert-lea-mba220.jpg)
No serious AEs, no retinal detachment or perforation, and no significant changes in intraocular pressure occurred. Most AEs were mild and resolved within 1 month.
![retina associates of kentucky retina associates of kentucky](https://www.retinaky.com/wp-content/themes/glacial/images/doc-3.jpg)
Eye-related AEs occurred in 76% of participants (16/21), including conjunctival hemorrhage (n = 5), retinal hemorrhage (n = 4), and vitreous floaters (n = 4). At baseline, median total area of GA was 13.4 mm 2 and median BCVA was 43 letters in the intervention eye. Surgery and palucorcel administration were performed in 21 participants at 8 sites by 8 different surgeons. Efficacy was evaluated as change in mean number of BCVA letters from baseline, proportion of participants gaining 15 BCVA letters or more, and growth rate of GA lesions at 12 months. Very high turnover rate within the staff. Our decades of clinical experience, commitment to research, passion for technological innovation. The physicians and staff of Retina Associates New Orleans are dedicated to diagnosing and treating common and rare retinal conditions. The tech position has decent pay, regular 8-5 hours, but the workers are not happy. Our team is available to answer your questions and schedule appointments at (504) 456-9061. Safety assessments included treatment-emergent adverse events (AEs), immunologic assessments, and ophthalmologic evaluations. The staff morale is very low and the clinical manager is noted by most of the staff to be an unapproachable 'hothead'. Participants received a subretinal injection of palucorcel, 3.0 × 10 5 cells in 50 μl, using the custom-designed delivery system and surgical procedure. Exclusion criteria included neovascular AMD in the intervention eye, glaucoma with intraocular pressure of 25 mmHg or more, or other significant ophthalmologic conditions. Participants were 55 to 90 years with GA secondary to age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) of 20/80 to 20/800. To evaluate safety and successful use of a novel subretinal delivery system and suprachoroidal surgical approach and safety and activity of human umbilical tissue-derived cells (palucorcel) via a novel delivery system in patients with geographic atrophy (GA).
![Retina associates of kentucky](https://loka.nahovitsyn.com/49.jpg)